Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia

A study of the eastern cooperative oncology group

Janice P. Dutcher, Lynn Eudey, Peter H. Wiernik, Elisabeth M. Paietta, John M. Bennett, Zalmen Arlin, Robert Kellermeyer, Jacob Rowe, Michael O'Connell, Martin Oken, Peter A. Cassileth

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

A total of 40 evaluable patients were treated for blastic crisis of chronic myelogenous leukemia with mitoxantrone, 12 mg/m2 per day for three days and 5-azacytidine 150 mg/m2 per day for 5 days. Toxicity was primarily hematologic and was manageable. The overall response rate was 23%, including five complete responders, two partial responders, and two with hematologic improvement. Cytogenetic and immunophenotypic characterization of the leukemia was performed on all patients with aspirable bone marrow, and these results were correlated with response and survival, but did not have predictive value once the patient was in blastic crisis. Only initial platelet count (p = 0.02), hemoglobin (p = 0.03), and lower white blood cell count (p = 0.09) were somewhat predictive of response. Lack of hepatic involvement (p = 0.05), lower white blood cell count (0.05), and higher platelet count (p = 0.02) were predictive of prolonged survival. Although response did not strongly correlate with survival, one third of responders were alive at one year. This regimen produces results similar to those of other recently published regimens in this disease. Earlier intervention and more effective therapy is necessary in these patients.

Original languageEnglish (US)
Pages (from-to)770-775
Number of pages6
JournalLeukemia
Volume6
Issue number8
StatePublished - Aug 1992

Fingerprint

Blast Crisis
Azacitidine
Mitoxantrone
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Platelet Count
Leukocyte Count
Survival
Cytogenetics
Leukemia
Hemoglobins
Bone Marrow
Liver

ASJC Scopus subject areas

  • Hematology
  • Cancer Research

Cite this

Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia : A study of the eastern cooperative oncology group. / Dutcher, Janice P.; Eudey, Lynn; Wiernik, Peter H.; Paietta, Elisabeth M.; Bennett, John M.; Arlin, Zalmen; Kellermeyer, Robert; Rowe, Jacob; O'Connell, Michael; Oken, Martin; Cassileth, Peter A.

In: Leukemia, Vol. 6, No. 8, 08.1992, p. 770-775.

Research output: Contribution to journalArticle

Dutcher, JP, Eudey, L, Wiernik, PH, Paietta, EM, Bennett, JM, Arlin, Z, Kellermeyer, R, Rowe, J, O'Connell, M, Oken, M & Cassileth, PA 1992, 'Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the eastern cooperative oncology group', Leukemia, vol. 6, no. 8, pp. 770-775.
Dutcher, Janice P. ; Eudey, Lynn ; Wiernik, Peter H. ; Paietta, Elisabeth M. ; Bennett, John M. ; Arlin, Zalmen ; Kellermeyer, Robert ; Rowe, Jacob ; O'Connell, Michael ; Oken, Martin ; Cassileth, Peter A. / Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia : A study of the eastern cooperative oncology group. In: Leukemia. 1992 ; Vol. 6, No. 8. pp. 770-775.
@article{7a7f54361ada485387a5a728a414ec60,
title = "Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia: A study of the eastern cooperative oncology group",
abstract = "A total of 40 evaluable patients were treated for blastic crisis of chronic myelogenous leukemia with mitoxantrone, 12 mg/m2 per day for three days and 5-azacytidine 150 mg/m2 per day for 5 days. Toxicity was primarily hematologic and was manageable. The overall response rate was 23{\%}, including five complete responders, two partial responders, and two with hematologic improvement. Cytogenetic and immunophenotypic characterization of the leukemia was performed on all patients with aspirable bone marrow, and these results were correlated with response and survival, but did not have predictive value once the patient was in blastic crisis. Only initial platelet count (p = 0.02), hemoglobin (p = 0.03), and lower white blood cell count (p = 0.09) were somewhat predictive of response. Lack of hepatic involvement (p = 0.05), lower white blood cell count (0.05), and higher platelet count (p = 0.02) were predictive of prolonged survival. Although response did not strongly correlate with survival, one third of responders were alive at one year. This regimen produces results similar to those of other recently published regimens in this disease. Earlier intervention and more effective therapy is necessary in these patients.",
author = "Dutcher, {Janice P.} and Lynn Eudey and Wiernik, {Peter H.} and Paietta, {Elisabeth M.} and Bennett, {John M.} and Zalmen Arlin and Robert Kellermeyer and Jacob Rowe and Michael O'Connell and Martin Oken and Cassileth, {Peter A.}",
year = "1992",
month = "8",
language = "English (US)",
volume = "6",
pages = "770--775",
journal = "Leukemia",
issn = "0887-6924",
publisher = "Nature Publishing Group",
number = "8",

}

TY - JOUR

T1 - Phase II study of mitoxantrone and 5-azacytidine for accelerated and blast crisis of chronic myelogenous leukemia

T2 - A study of the eastern cooperative oncology group

AU - Dutcher, Janice P.

AU - Eudey, Lynn

AU - Wiernik, Peter H.

AU - Paietta, Elisabeth M.

AU - Bennett, John M.

AU - Arlin, Zalmen

AU - Kellermeyer, Robert

AU - Rowe, Jacob

AU - O'Connell, Michael

AU - Oken, Martin

AU - Cassileth, Peter A.

PY - 1992/8

Y1 - 1992/8

N2 - A total of 40 evaluable patients were treated for blastic crisis of chronic myelogenous leukemia with mitoxantrone, 12 mg/m2 per day for three days and 5-azacytidine 150 mg/m2 per day for 5 days. Toxicity was primarily hematologic and was manageable. The overall response rate was 23%, including five complete responders, two partial responders, and two with hematologic improvement. Cytogenetic and immunophenotypic characterization of the leukemia was performed on all patients with aspirable bone marrow, and these results were correlated with response and survival, but did not have predictive value once the patient was in blastic crisis. Only initial platelet count (p = 0.02), hemoglobin (p = 0.03), and lower white blood cell count (p = 0.09) were somewhat predictive of response. Lack of hepatic involvement (p = 0.05), lower white blood cell count (0.05), and higher platelet count (p = 0.02) were predictive of prolonged survival. Although response did not strongly correlate with survival, one third of responders were alive at one year. This regimen produces results similar to those of other recently published regimens in this disease. Earlier intervention and more effective therapy is necessary in these patients.

AB - A total of 40 evaluable patients were treated for blastic crisis of chronic myelogenous leukemia with mitoxantrone, 12 mg/m2 per day for three days and 5-azacytidine 150 mg/m2 per day for 5 days. Toxicity was primarily hematologic and was manageable. The overall response rate was 23%, including five complete responders, two partial responders, and two with hematologic improvement. Cytogenetic and immunophenotypic characterization of the leukemia was performed on all patients with aspirable bone marrow, and these results were correlated with response and survival, but did not have predictive value once the patient was in blastic crisis. Only initial platelet count (p = 0.02), hemoglobin (p = 0.03), and lower white blood cell count (p = 0.09) were somewhat predictive of response. Lack of hepatic involvement (p = 0.05), lower white blood cell count (0.05), and higher platelet count (p = 0.02) were predictive of prolonged survival. Although response did not strongly correlate with survival, one third of responders were alive at one year. This regimen produces results similar to those of other recently published regimens in this disease. Earlier intervention and more effective therapy is necessary in these patients.

UR - http://www.scopus.com/inward/record.url?scp=0026786294&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026786294&partnerID=8YFLogxK

M3 - Article

VL - 6

SP - 770

EP - 775

JO - Leukemia

JF - Leukemia

SN - 0887-6924

IS - 8

ER -